Zealand Pharma A/S (NASDAQ:ZEAL)’s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $30.34, but opened at $31.27. Zealand Pharma A/S shares last traded at $31.27, with a volume of 60 shares.
Separately, Zacks Investment Research cut shares of Zealand Pharma A/S from a “hold” rating to a “sell” rating in a research note on Wednesday, March 17th.
The company has a market cap of $1.40 billion, a P/E ratio of -14.11 and a beta of 1.19. The business’s 50 day simple moving average is $32.00 and its 200 day simple moving average is $35.68.
Institutional investors and hedge funds have recently made changes to their positions in the business. Jane Street Group LLC grew its holdings in Zealand Pharma A/S by 35.5% during the 4th quarter. Jane Street Group LLC now owns 35,707 shares of the company’s stock valued at $1,283,000 after buying an additional 9,352 shares in the last quarter. Morgan Stanley grew its holdings in Zealand Pharma A/S by 4.5% during the 3rd quarter. Morgan Stanley now owns 8,360 shares of the company’s stock valued at $321,000 after buying an additional 357 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in Zealand Pharma A/S by 320.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 958 shares of the company’s stock valued at $36,000 after buying an additional 730 shares in the last quarter. 4.32% of the stock is owned by institutional investors and hedge funds.
Zealand Pharma A/S Company Profile (NASDAQ:ZEAL)
Zealand Pharma A/S, a biotechnology company, engages in the discovery and development of peptide-based medicines in Denmark. It has a portfolio of medicines in development stage focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide under the brand names of Adlyxin, Lyxumia, Soliqua 100/33, and Suliqua.
Read More: What is the S&P 500 Index?
Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.